Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholinergic and peptidergic systems in PSP

F Javoy-Agid1

  • 1INSERM U 289, Hôpital de la Salpêtrière, Paris, France.

Journal of Neural Transmission. Supplementum
|January 1, 1994
PubMed
Summary

Progressive Supranuclear Palsy (PSP) involves significant cholinergic neuron loss, impacting brain areas crucial for motor control. Unlike other dementias, PSP does not show cortical cholinergic deficiency, distinguishing it from Alzheimer's and Parkinson's disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of Bcl-2 in adult human brain regions with special reference to neurodegenerative disorders.

Journal of neurochemistry·1997
Same author

Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.

Histology and histopathology·1997
Same author

I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease.

Neurochemistry international·1997
Same author

DA uptake sites, D1 and D2 receptors, D2 and preproenkephalin mRNAs and Fos immunoreactivity in rat striatal subregions after partial dopaminergic degeneration.

The European journal of neuroscience·1996
Same author

Clinical and pathological features in hydrocarbon-induced parkinsonism.

Annals of neurology·1996
Same author

Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis.

Brain : a journal of neurology·1996

Area of Science:

  • Neuroscience
  • Neuropathology
  • Neurochemistry

Background:

  • Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder.
  • It presents with characteristic motor and oculomotor deficits.
  • Understanding the underlying neurochemical changes is crucial for diagnosis and treatment.

Purpose of the Study:

  • To investigate the neurochemical profile of PSP, focusing on cholinergic systems.
  • To compare PSP's neurochemical deficits with those in Alzheimer's disease (AD) and Parkinson's disease with dementia (PDD).
  • To examine peptide concentrations, particularly somatostatin, in PSP brains.

Main Methods:

  • Analysis of post-mortem brain tissue from PSP patients.
  • Measurement of neurotransmitter levels, specifically acetylcholine and related markers.
  • Quantification of peptide concentrations in various brain regions.

Main Results:

  • PSP exhibits widespread cholinergic deficits, primarily in the basal ganglia, mesencephalon, and pons.
  • These deficits correlate with the motor and oculomotor symptoms of PSP.
  • Unlike AD and PDD, PSP brains do not show significant cortical cholinergic deficiency.
  • Peptide levels, including somatostatin, are generally normal in PSP subcortical areas, contrasting with reduced somatostatin in AD and PDD cortical areas.

Conclusions:

  • The distinct pattern of cholinergic damage in PSP differentiates it from AD and PDD.
  • Cholinergic deficits in specific subcortical nuclei are key neuropathological features of PSP.
  • Further research into PSP's unique neurochemical profile may reveal novel therapeutic targets.

Related Experiment Videos